Change In The Number Of Votes Relating To BioTie Therapies Corp.'s Shares

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!



Biotie Therapies Corp.          Stock Exchange Release    3 June 2014 at 1 p.m.

Change in the number of votes relating to Biotie Therapies Corp.'s shares

The Swiss subsidiary of Biotie Therapies Corp. ("Biotie" or the "Company"), Biotie Therapies AG (previously Synosia Therapeutics Holding AG and Biotie Therapies Holding AG) has conveyed Biotie shares against consideration pursuant to the option programs as follows:

May 2014 Total (5/2011-
5/2014)
Options
 outstanding
    166,243  8,642,309           4,254,667

The conveyance of Biotie shares relates to the option plan of Synosia Therapeutics Holding AG (currently Biotie Therapies Holding AG, "Synosia") acquired by Biotie in February 2011. According to such Synosia share option plan, options have been granted to employees, former directors and consultants. In connection with the completion of the acquisition of Synosia, the option plan was amended so that instead of shares in Synosia an aggregate maximum of 14,912,155 shares in Biotie may be subscribed based on the plan. Biotie issued these 14,912,155 shares to its current subsidiary Synosia in connection with the acquisition to be further conveyed to the option holders when they potentially exercise their option rights in accordance with the terms and conditions of the option program.

The conveyed shares previously held as Treasury shares have not carried any voting rights. The conveyance does not affect the number of registered shares.

After the conveyances the changes are as follows:

The increase
of vote
of the Company
May 2014
A total amount of
voting rights:
The number of the
 Company's share held
 by the Biotie Group
May 2014
The total number
of registered
shares
166,243        447,687,142              8,345,256 456,032,398

Turku, 3 June 2014

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com 





Help employers find you! Check out all the jobs and post your resume.

Back to news